UCB SA (OTCMKTS:UCBJF – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $195.88 and last traded at $195.88, with a volume of 87 shares traded. The stock had previously closed at $174.00.
UCB Stock Performance
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average price of $180.30 and a 200-day moving average price of $164.98.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- How to Effectively Use the MarketBeat Ratings Screener
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Investing in Construction Stocks
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
